Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tezacaftor

- PMLiVE

Vertex shares positive late-stage results for triple combination cystic fibrosis treatment

The company compared the treatment to its current triple cystic fibrosis therapy

- PMLiVE

MHRA extends licence of Vertex’s cystic fibrosis drugs for young children

Kaftrio and Kalydeco are now approved for use in certain patients aged two to five years

- PMLiVE

Pioneering research collaboration seeks cure for cystic fibrosis

Backed by the non-profit Cystic Fibrosis Foundation and venture capital group Flagship, Pioneering Medicines will identify and develop genetic therapies for CF

- PMLiVE

Moderna inks R&D agreements with Vertex and Chiesi

Biotech agrees to separate deals for the development of gene-editing and mRNA therapies

- PMLiVE

Vertex’s triple combination CF therapy to become available on the NHS

The drug will immediately become available to thousands of cystic fibrosis patients

- PMLiVE

Making a difference with patient support

A clear understanding of the patient journey and experience is pivotal in designing patient support programmes

Bedrock Healthcare Communications

- PMLiVE

Vertex continues upward trajectory with French Orkambi deal

Comes on the heels of similar reimbursement deal in England

- PMLiVE

Vertex, NHS England and NICE finally reach agreement for Orkambi

Deal also includes Vertex’s other licensed cystic fibrosis medicines

- PMLiVE

Vertex scores FDA approval for CF triple therapy Trikafta

Decision comes only a few months after therapy was filed

- PMLiVE

Vertex files cystic fibrosis triple therapy with FDA

A landmark for company - but pricing controversy awaits

- PMLiVE

Orkambi row: government now considering Crown Use licensing

MPs call for radical solutions as deadlock remains

- PMLiVE

Vertex eyes Duchenne market with Exonics, CRISPR deals

Biotech has gene-editing expertise

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links